Pfizer brought Pico's innovative drug Xibek to the Expo and held the first anniversary celebration of Sutanmin

Shanghai, November 7, 2021/PRNewswire/ - At the 4th CIIE, Pfizer brought Abrocitinib for the treatment of moderate to severe atopic dermatitis on the stage of the CIIE for the first time.

Professor Yao Zhirong, director of the Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, said: “The CIBINQO (Abrocitinib) demonstrated this time is a highly selective JAK1 inhibitor.

It is worth mentioning that the innovative dermatology drug PDE-4 inhibitor sultamamine (cleborol), which first appeared in the second CIIE and was born in the third CIIE, will be in the 4th CIIE.

The "Blue Book on Long-term Management of AD Patients in China" was initiated by the Beijing Great Medical Public Welfare Foundation.

The interim results of the "Blue Book on Long-term Management of AD Patients in China" pointed out that AD requires long-term treatment, and a good doctor-patient relationship should be established to obtain the best curative effect through the entire course of disease management

The purpose of maintenance treatment is to continue to give patients continuous treatment when the symptoms of AD reach the remission period, so as to stabilize the condition and reduce the possibility of recurrence

AD has repeated itching as the main symptom, which can cause anxiety and depression in severe cases

Atopic Dermatitis (AD) is a special type of eczema with a family genetic tendency, showing chronic, recurrent, and inflammatory characteristics, with dry skin, chronic eczema-like skin lesions and obvious itching as the basic clinical manifestations

Although AD can occur at any age, the clinical manifestations of patients in each age group are different

"Repetitive itching is the most important symptom of AD.

Innovative drugs fill the gap in treatment and bring dawn to breakthrough treatment of immune skin diseases

For the AD, mainly in clinical drug treatment, common drugs include topical corticosteroids (the TCS), topical calcineurin inhibitors (TCI), phosphoric external PDE inhibitors.

For patients with moderate to severe AD, the main demand is to quickly relieve itching, but the effects of currently available drugs are very limited, and the timeliness, safety, convenience, and accessibility of the drugs need to be improved

"As the first and only topical PDE-4 inhibitor approved for AD in China, Sutanmin has a deep relationship with the CIIE.

Well-known experts and senior scholars from the field of atopic dermatitis in China gathered together to conduct in-depth exchanges and discussions on disease knowledge, diagnosis and treatment status, long-term management, etc.

Note: CIBINQO (Abrocitinib) has not yet been approved for listing in China

Source: Pfizer